SEC Form 4 · accession 0001209191-18-005804
Intellia Therapeutics, Inc. · NTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Graeme Bell
Officer — EVP, Chief Financial Officer
Period of report
Jan 25, 2018
Accepted (ET)
Jan 29, 2018 · 3:31 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001652130
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $22.78 | Jan 25, 2018 | A | 25,000 | A | — | Jan 24, 2028 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1This option was granted on January 25, 2018 with respect to 25,000 shares of Common Stock, with 25% vesting on January 25, 2019 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.